Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells

International Journal of Cancer

Volumn 105, Issue 5, 2003, Pages 617-624

  Perego, Paola ^a   Gatti, Laura ^a   Righetti, Sabina C ^a   Beretta, Giovanni L ^a   Carenini, Nives ^a   Corna, Elisabetta ^a   Dal Bo, Laura ^a   Tinelli, Stella ^a   Colangelo, Donato ^b   Leone, Roberto ^c   Apostoli, Piero ^d   Lombardi, Luciano ^a   Beggiolin, Gino ^e   Piazzoni, Laura ^e   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Novuspharma SpA   (Italy)

Author keywords

Ovarian carcinoma; Platinum drugs; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; BBR 3464; CARMUSTINE; CISPLATIN; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DNA; DOXORUBICIN; MELPHALAN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P21; PROTEIN P53; RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DNA BINDING; ELECTRON MICROSCOPY; GENE EXPRESSION; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MISMATCH REPAIR; OVARY CARCINOMA; PLASMID; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE PAIR MISMATCH; CARMUSTINE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE; GLUTATHIONE; HUMANS; MELPHALAN; METALLOTHIONEIN; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN KINASES; TUMOR CELLS, CULTURED;

EID: 0037837096     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11140     Document Type: Article

References (33)

1. Herrin VE, Thigpen JT. Chemotherapy for ovarian cancer: current concepts. Semin Surg Oncol 1999;17:181-8.
2. Perez RP, Hamilton TC, Ozols RF. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 1990;48:19-27.
3. Giaccone G. Clinical perspectives on platinum resistance. Drugs 2000;59:37-8.
4. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
5. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1992;52:822-8.
6. Perego P, Zunino F, Carenini N, Giuliani F, Spinelli S, Howell SB. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe Rad mutants. Mol Pharmacol 1998;54:213-9.
7. Perego P, Caserini C, Gatti L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano I, Leone R, Spinelli S, Pezzoni G, Manzotti C, et al. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol Pharmacol 1999;55:528-34.
8. Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, et al. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999;80:1912-9.
9. Manzotti C, Pratesi G, Menta E, Di Domenico R, Cavalletti E, Fiebig HH, Kelland LR, Farrell N, Polizzi D, Supino R, Pezzoni G, Zunino F. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin Cancer Res 2000;6:2626-34.
10. Maniatis T, Fritsh EF, Sambrook J, editors. Molecular cloning: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1982.
11. Bonetti A, Apostoli P, Zanninelli N, Pavanel F, Colombatti M, Cetto GL, Franceschi T, Sperotto L, Leone R. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res 1996;2:1829-35.
12. Perego P, Righetti SC, Supino R, Delia D, Caserini C, Carenini N, Bedognè B, Broome E, Krajewski S, Reed JC, Zunino F. Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 1997;2:540-8.
13. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 1969; 27:502-22.
14. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-62.
15. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000;18:3936-45.
16. Beretta GL, Righetti SC, Lombardi L, Zunino F, Perego P. Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells. Ultrastructural Pathol 2002;26:331-4.
17. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 1991;64:215-20.
18. Kondo Y, Kuo SM, Watkins SC, Lazo JS. Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. Cancer Res 1995;55:474-7.
19. O'Connor PM. Mammalian G1 and G2 phase check-points. Cancer Surv 1997;29:151-82.
20. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996;32:921-6.
21. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56:3087-90.
22. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin. A review. Br J Cancer 1993;67:1171-6.
23. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R, Arcamone F. Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther 1997;76:177-85.
24. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996;56:1834-41.
25. Anthoney DA, Mcllwrath AJ, Gallagher WM, Edlin ARM, Brown R. Microsatellite instability, apoptosis and loss of p53 function in drug-resistant tumor cells. Cancer Res 1996;56:1374-81.
26. Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R, Apostoli P, Cassinelli G, Gambetta RA, et al. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochem Pharmacol 1998;55:1247-54.
27. Fink D, Nebel S, Aebi Szheng H, Cenni B, Nehme A, Christen RD, Howell SB. The role of DNA Mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-6.
28. Gottifredi V, Karni-Schmidt O, Shieh S-Y, Prives C. p53 down-regulates CHK1 through p21 and retinoblastoma protein. Mol Cell Biol 2001;21:1066-76.
29. Damia G, Sanchez J, Erba E, Broggini M. DNA damage induces p53-dependent down-regulation of hCHK1. J Biol Chem 2001;276: 10641-5.
30. Sampath D, Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoints pathways. Curr Opin Oncol 2001;13:484-90.
31. Orlandi L, Colella G, Bearzatto A, Abolafio G, Manzotti C, Daidone MG, Zaffaroni N. Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian carcinoma cell lines: interference with cell cycle progression and induction of apoptosis. Eur J Cancer 2001;37:649-59.
32. Riccardi A, Meco D, Ferlini C, Servirei T, Carelli G, Segni G, Manzotti C, Riccardi R. In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR3464 in neuroblastoma. Cancer Chemother Pharmacol 2001;47:498-504.
33. Servidei T, Ferlini C, Riccardi A, Meco D, Scambia G, Segni G, Manzotti C, Riccardi R. The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 2001;37:930-8.